Novavax (NVAX) Free Cash Flow (2010 - 2026)
Novavax (NVAX) posted quarterly Free Cash Flow of -$33.7 million for Q1 2026, up 82.0% year-over-year from -$18.5 million in Q1 2025, and up 24.82% quarter-over-quarter from -$44.8 million in Q4 2025.
Novavax (NVAX) Free Cash Flow (2010 - 2026) Analysis & Trends
Novavax's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$33.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 82.0% year-over-year to -$33.7 million; the TTM figure through Mar 2026 stood at -$96.8 million (up 49.25% YoY), while the FY2025 annual figure was -$250.2 million, down 183.26% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$33.7 million, up from -$44.8 million in the prior quarter.
- The five-year high for Free Cash Flow was $314.9 million in Q2 2024, with the low at -$329.3 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$105.3 million (2022), against an average of -$89.1 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 223.7% in 2022, then jumped 282.27% in 2024.
- Novavax's Free Cash Flow stood at -$55.7 million in 2022, then tumbled by 150.84% to -$139.7 million in 2023, then slipped by 23.52% to -$172.6 million in 2024, then soared by 74.06% to -$44.8 million in 2025, then rose by 24.82% to -$33.7 million in 2026.
- Business Quant data shows NVAX's Free Cash Flow at -$33.7 million in Q1 2026, -$44.8 million in Q4 2025, and $109.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -73.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.40 Mn |
| Jun 30, 2026 | -73.40 Mn |
| Mar 31, 2026 | -33.67 Mn |
| Mar 31, 2026 | -33.67 Mn |
| Dec 31, 2025 | -44.79 Mn |
| Dec 31, 2025 | -44.79 Mn |
| Sep 30, 2025 | 109.06 Mn |
| Sep 30, 2025 | 109.06 Mn |
| Jun 30, 2025 | -127.37 Mn |
| Jun 30, 2025 | -127.37 Mn |
| Mar 31, 2025 | -187.10 Mn |
| Mar 31, 2025 | -187.10 Mn |
| Dec 31, 2024 | -172.62 Mn |
| Dec 31, 2024 | -172.62 Mn |
| Sep 30, 2024 | -145.80 Mn |
| Sep 30, 2024 | -145.80 Mn |
| Jun 30, 2024 | 314.86 Mn |
| Jun 30, 2024 | 314.86 Mn |
| Mar 31, 2024 | -84.76 Mn |
| Mar 31, 2024 | -84.76 Mn |